Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] Business Segments - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products segment offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the micronutrient agricultural market [2] Upcoming Events - Balchem Corporation will present at the CJS Annual New Ideas Summer Conference on July 10, 2025, with key executives including Ted Harris, Martin Bengtsson, and Allison Baurichter [1]

Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the micronutrient agricultural market [2] Upcoming Events - Balchem Corporation will present at the Wells Fargo Industrials and Materials Conference on June 11, 2025 [1] - Key executives attending the conference include Ted Harris (Chairman, CEO, and President), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations) [1]

Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical industries [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the agricultural market [2] Upcoming Events - Balchem Corporation will participate in the dbAccess Global Consumer Conference on June 4, 2025 [1] - Key executives, including Ted Harris (Chairman, CEO, and President) and Martin Bengtsson (CFO), will represent the company at the conference [1]

Financial Data and Key Metrics Changes - The company reported record first quarter consolidated revenue of $251 million, a 4.5% increase year-over-year [16] - GAAP earnings from operations increased by 22.4% to $51 million, while adjusted EBITDA reached a record $66 million, up 8.9% [21][16] - Consolidated net income was $37 million, reflecting a 27.8% increase, translating to diluted net earnings per share of $1.13, up 27% [23][17] Business Segment Performance - Human Nutrition & Health segment generated record sales of $158 million, a 3.7% increase, with earnings from operations rising 14.2% to $38 million [24][25] - Animal Nutrition & Health segment saw sales of $57 million, up 6.2%, with earnings from operations increasing 154.2% to $5 million [26][27] - Specialty Products segment delivered sales of $33 million, a 5.3% increase, with earnings from operations rising 16.9% to $10 million [29][30] Market Data and Key Metrics Changes - The company imports approximately $100 million of raw materials annually, with less than $15 million from China, indicating a diversified supply chain [11] - Exports from the U.S. to other countries amount to approximately $90 million annually, with current tariffs having an immaterial impact on the company [13] Company Strategy and Industry Competition - The company is well-positioned to manage the evolving global trade environment, leveraging a strong manufacturing footprint and supply chain flexibility [9][10] - The management emphasized the ability to raise prices to offset tariff impacts, similar to strategies employed during the post-COVID inflationary period [12][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business model despite uncertainties in global demand due to trade disputes [14][15] - The company anticipates healthy demand across end markets, with no current signs of demand deterioration [43] Other Important Information - Cash flows from operations were $36 million, with free cash flow of $31 million, and the company ended the quarter with $50 million in cash [24] - The effective tax rate for the first quarter was 22.7%, with expectations for the full year to be in the range of 22% to 23% [22][73] Q&A Session Summary Question: Impacts of tariffs and trade war - Management indicated confidence in managing raw material costs and the ability to raise prices if necessary, while expressing concerns about potential impacts on global demand [39][42][44] Question: Update on European Chinese dumping ruling - The company has filed an anti-dumping case accepted by the EU, with expectations for a response in the next three to six months [48][49] Question: Tailwinds for 2025 and product performance - Management highlighted strong growth in the choline and vitamin K2 categories, with expectations for continued growth in the Nutrients portfolio [58][60] Question: Debt repayment strategy - The company prioritizes organic growth investments and is evaluating M&A opportunities while continuing to pay down debt [70][71] Question: Effective tax rate expectations - The effective tax rate for the remainder of the year is expected to be around 22% to 22.5% based on first quarter results [73]

Financial Performance - Balchem's 2024 sales reached $954 million[9] - The company's 2024 adjusted EBITDA was $250 million, with a margin of 26.3%[12] - In Q1 2025, sales grew by 4.5% to $250.5 million from $239.7 million in Q1 2024[57] - Adjusted EBITDA for Q1 2025 increased by 8.9% to $66.3 million compared to $60.9 million in Q1 2024[59] - Adjusted net earnings for Q1 2025 rose by 19.2% to $40.0 million from $33.6 million in Q1 2024[61] - Adjusted EPS for Q1 2025 grew by 18.4% to $1.22 per share from $1.03 per share in Q1 2024[63] Business Segments - Human Nutrition & Health accounted for 63% of Balchem's 2024 revenue[15] - Animal Nutrition & Health contributed 23% to the company's 2024 revenue[15] - Specialty Products represented 14% of Balchem's 2024 revenue[15] Sustainability - Balchem reached 1.2 billion people in 2024 through its products[86] - The company has reduced its Scope 1 and 2 GHG emissions by 32%, surpassing its 2030 goal[91] - Balchem has reduced its water withdrawal by 15% from the baseline and is on track to meet its 2030 goal[93]

Financial Data and Key Metrics Changes - The company reported record first quarter consolidated revenue of $251 million, a 4.5% increase year-over-year [16] - GAAP earnings from operations increased by 22.4% to $51 million, while adjusted EBITDA reached a record $66 million, up 8.9% [21][16] - Consolidated net income was $37 million, reflecting a 27.8% increase, translating to diluted net earnings per share of $1.13, up 27% [23][17] Business Segment Performance - The Human Nutrition & Health segment generated record sales of $158 million, a 3.7% increase, with earnings from operations rising 14.2% to $38 million [24][25] - The Animal Nutrition & Health segment saw sales of $57 million, up 6.2%, with earnings from operations increasing 154.2% to $5 million [26][27] - The Specialty Products segment delivered sales of $33 million, a 5.3% increase, with earnings from operations rising 16.9% to $10 million [29][30] Market Data and Key Metrics Changes - The company imports approximately $100 million of raw materials annually, with less than $15 million from China, indicating a diversified supply chain [11] - The impact of current tariffs is estimated at approximately $20 million, with the company planning to offset half through alternative sourcing and pricing actions [12] Company Strategy and Industry Competition - The company is well-positioned to manage the evolving global trade environment, leveraging a strong manufacturing footprint and supply chain flexibility [9][10] - The management expressed confidence in the long-term growth outlook, emphasizing the resilience of the business model amid market uncertainties [32] Management's Comments on Operating Environment and Future Outlook - Management noted that demand remains healthy across end markets, with no current signs of recessionary impacts affecting order books [43][44] - The company has a solid track record of delivering results in various market conditions, having achieved 23 consecutive quarters of year-over-year growth in adjusted EBITDA [45] Other Important Information - Cash flows from operations were reported at $36 million, with free cash flow of $31 million and $50 million in cash on the balance sheet [24] - The effective tax rate for the first quarter was 22.7%, with expectations for the full year to be in the range of 22% to 23% [22][73] Q&A Session Summary Question: Impacts of tariffs and trade war - Management acknowledged the complexity of tariff impacts but expressed confidence in their ability to manage costs through supply chain flexibility and pricing strategies [39][42] Question: Update on European Chinese dumping ruling - The company has filed an anti-dumping case accepted by the EU, with expectations for a response in the next three to six months [48][49] Question: Tailwinds for 2025 and product performance - Management highlighted strong growth in the choline and vitamin K2 categories, with expectations for continued growth driven by new product launches [58][60] Question: Debt repayment strategy - The company prioritizes organic growth investments and is evaluating M&A opportunities while continuing to pay down debt [70][71] Question: Effective tax rate expectations - The effective tax rate for the remainder of the year is expected to be around 22% to 22.5% based on first-quarter performance [73]

Financial Performance - Total net sales for the three months ended March 31, 2025, were $250,519,000, representing a 4.5% increase from $239,659,000 in the same period of 2024[84] - Gross margin increased to $88,168,000 for the first quarter of 2025, up 8.2% from $81,514,000 in 2024, with gross margin as a percentage of net sales rising to 35.2%[86] - Earnings from operations for the first quarter of 2025 were $51,015,000, a 22.4% increase compared to $41,676,000 in 2024[89] - Net earnings for the first quarter of 2025 were $37,053,000, reflecting a 27.8% increase from $28,986,000 in 2024[84] Segment Performance - Human Nutrition & Health segment net sales grew by 3.7% to $158,457,000, driven by higher sales in food ingredients and nutrients[88] - Animal Nutrition & Health segment net sales increased by 6.2% to $57,277,000, primarily due to higher sales in ruminant species markets[88] - Specialty Products segment net sales rose by 5.3% to $33,275,000, attributed to higher sales in performance gases and plant nutrition[88] Operating Expenses and Cash Flow - Operating expenses decreased by 6.7% to $37,153,000 in the first quarter of 2025, down from $39,838,000 in 2024[87] - Cash flows from operating activities increased by 9.2% to $36,457 for the three months ended March 31, 2025, compared to $33,388 in 2024[95] - Cash flows used in investing activities decreased by 12.3% to $(5,912) in 2025 from $(6,739) in 2024[95] - Total investments in property, plant, and equipment and intangible assets were $5,559 for the three months ended March 31, 2025, down from $6,910 in 2024[97] Working Capital and Cash Position - Cash and cash equivalents increased to $49,901 as of March 31, 2025, up from $49,515 at December 31, 2024, with $44,380 held by foreign subsidiaries[94] - Working capital rose to $200,684 at March 31, 2025, compared to $156,085 at December 31, 2024, reflecting an increase of $44,599[94] Debt and Dividend Payments - The company borrowed $29,000 in 2025 to fund the 2024 dividend and bonus payments, with total loan payments also amounting to $29,000[98] - Dividend payments increased to $28,263 in the three months ended March 31, 2025, compared to $25,555 in 2024[100] Tax and Liabilities - The effective tax rate for the first quarter of 2025 was 22.7%, up from 21.3% in 2024, primarily due to lower tax benefits from stock-based compensation[91] - The deferred compensation liability was $11,653 as of March 31, 2025, up from $11,470 at December 31, 2024[104] Risk Factors - A 100 basis point change in interest rates would result in an approximate $1,900 increase or decrease in annual interest expense[107] - The company is exposed to foreign currency exchange risk due to the financial condition of foreign subsidiaries being reported in local currencies[108] Future Outlook - The company is actively pursuing additional acquisition candidates and expects to generate sufficient cash flow to fund working capital and necessary capital investments[93]

Financial Data and Key Metrics Changes - The company reported record first quarter consolidated revenue of $251 million, a 4.5% increase year-over-year [12][13] - GAAP earnings from operations increased by 22.4% compared to the prior year [13][18] - Adjusted EBITDA reached a record $66 million, up 8.9%, with an adjusted EBITDA margin of 26.5%, an increase of 106 basis points from the prior year [13][17] - Consolidated net income for the quarter was $37 million, a 27.8% increase, translating to diluted net earnings per share of $1.13, up 27% year-over-year [13][19] Business Segment Performance - The Human Nutrition and Health segment generated record sales of $158 million, a 3.7% increase, with earnings from operations of $38 million, up 14.2% [19][20] - The Animal Nutrition and Health segment reported sales of $57 million, a 6.2% increase, with earnings from operations of $5 million, up 154.2% [21][22] - The Specialty Products segment delivered sales of $33 million, a 5.3% increase, with earnings from operations of $10 million, up 16.9% [22][23] Market Data and Key Metrics Changes - The company imports approximately $100 million of raw materials annually, with less than $15 million from China, indicating a diversified supply chain [7][8] - The company exports approximately $90 million annually, with current tariffs having an immaterial impact on exports [10][11] Company Strategy and Industry Competition - The company is well-positioned to manage through the changing global trade environment, leveraging a strong manufacturing and sales model [6][12] - The management emphasized the ability to raise prices to offset tariff impacts, similar to actions taken during the post-COVID inflationary period [9][30] - The company is focusing on organic growth and evaluating M&A opportunities, with a cautious approach due to current market uncertainties [50][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience amid evolving trade conditions, noting healthy demand across end markets [11][12] - The company is monitoring potential recessionary impacts on overall demand but currently sees no signs of demand weakening [11][31] - The management remains optimistic about growth in the Human Nutrition and Health segment, particularly in the Food Ingredients and Nutrients businesses [20][60] Other Important Information - The effective tax rate for the first quarter was 22.7%, with expectations for the full year to be in the range of 22% to 22.5% [18][53] - The company closed the quarter with $50 million in cash on the balance sheet and free cash flow of $31 million [19] Q&A Session Summary Question: Impact of tariffs and trade war - Management feels well-positioned to manage tariff impacts, expecting to offset half of the costs through supply chain flexibility and pricing actions [29][30] Question: Update on European Chinese dumping ruling - The company has filed an antidumping case accepted by the EU, expecting a response in three to six months, with confidence in the case's strength [35][36] Question: Tailwinds for 2025 - Management highlighted growth in choline and vitamin K2 categories, with strong demand and marketing efforts contributing to performance [40][42] Question: Debt repayment strategy - The company prioritizes organic growth investments, with ongoing debt repayment and potential share buybacks considered [50][52] Question: Breakdown of Human Nutrition and Health segment growth - The food ingredient business grew faster than the nutrients business, indicating strong performance across various product lines [58][60]

Core Viewpoint - Blachem (BCPC) reported quarterly earnings of $1.22 per share, missing the Zacks Consensus Estimate of $1.25 per share, but showing an increase from $0.89 per share a year ago, indicating a -2.40% earnings surprise [1] Financial Performance - The company posted revenues of $250.52 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.38% and up from $239.66 million year-over-year [2] - Over the last four quarters, Blachem has surpassed consensus EPS estimates only once [2] Stock Performance - Blachem shares have declined approximately 2.9% since the beginning of the year, while the S&P 500 has decreased by 8.6% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.28 on revenues of $252.28 million, and for the current fiscal year, it is $5.10 on revenues of $1.02 billion [7] - The estimate revisions trend for Blachem is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Chemical - Specialty industry, to which Blachem belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook may impact stock performance [8]

Financial Performance - Record net sales of $250.5 million, an increase of $10.9 million, or 4.5%, compared to the prior year quarter[5] - GAAP net earnings were $37.1 million, an increase of 27.8% from the prior year quarter[5] - Record Adjusted EBITDA was $66.3 million, an increase of 8.9% from the prior year quarter[5] - Net earnings for Q1 2025 were $37,053,000, a 28% increase from $28,986,000 in Q1 2024[21] - Adjusted net earnings for Q1 2025 were $40,017,000, compared to $33,584,000 in Q1 2024, representing a 19% increase[25] - EBITDA for Q1 2025 was $61,957,000, up from $55,273,000 in Q1 2024, indicating a 12% increase[27] Segment Performance - Human Nutrition and Health segment generated record sales of $158.5 million, an increase of $5.7 million, or 3.7% compared to the prior year quarter[8] - Animal Nutrition and Health segment generated quarterly sales of $57.3 million, an increase of $3.4 million, or 6.2% compared to the prior year quarter[8] - Specialty Products segment generated quarterly sales of $33.3 million, an increase of $1.7 million, or 5.3% compared to the prior year quarter[9] Cash Flow and Assets - Cash flows from operations were $36.5 million, with free cash flow of $31.0 million[12] - Free cash flow for Q1 2025 was $31,036,000, an increase from $26,815,000 in Q1 2024, marking an 15% growth[30] - Total assets as of March 31, 2025, were $1,617.6 million, an increase from $1,575.4 million at the end of 2024[19] Margins - Consolidated quarterly gross margin of $88.2 million increased by $6.7 million, or 8.2%, compared to the prior year comparable period[10] - Adjusted gross margin for Q1 2025 was $88,861,000, up from $82,218,000 in Q1 2024, reflecting a 8% increase[25] Tax and Dividends - The effective income tax rate for Q1 2025 was 22.7%, compared to 21.3% in Q1 2024[28] - Dividends paid in Q1 2025 totaled $28,263,000, compared to $25,555,000 in Q1 2024, reflecting an increase of 11%[21] Other Information - The company launched a new corporate website to enhance user experience and product insights[5] - Cash and cash equivalents at the end of Q1 2025 were $49,901,000, compared to $60,349,000 at the end of Q1 2024[21] - Capital expenditures for Q1 2025 were $5,559,000, down from $6,910,000 in Q1 2024, a decrease of 20%[21] - Proceeds from stock options exercised in Q1 2025 were $1,668,000, a significant decrease from $8,791,000 in Q1 2024[21]